

# Miguel A. Piris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/401662/publications.pdf>

Version: 2024-02-01

421  
papers

29,218  
citations

5876

81  
h-index

7333

152  
g-index

431  
all docs

431  
docs citations

431  
times ranked

29177  
citing authors

#	ARTICLE	IF	CITATIONS
1	PLCÎ³1/PKCÎ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1391-1400.e15.	0.3	5
2	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
3	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	3.2	22
4	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	2.8	7
5	Localized skin-limited blastic plasmacytoid dendritic cell neoplasm. <i>EJHaem</i> , 2022, 3, 560-562.	0.4	2
6	Search for the cause of anaemia and neutropenia in a patient with well-controlled systemic lupus erythematosus. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	0
7	CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. <i>Cancers</i> , 2022, 14, 2154.	1.7	1
8	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy. <i>EJHaem</i> , 2022, 3, 722-733.	0.4	1
9	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
10	Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. <i>British Journal of Haematology</i> , 2021, 192, 82-99.	1.2	5
11	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	1.5	20
12	Mycosis Fungoides and SÅ©zary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. <i>Cancers</i> , 2021, 13, 1931.	1.7	23
13	Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy. <i>Hemato</i> , 2021, 2, 281-304.	0.2	1
14	Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes. <i>Leukemia and Lymphoma</i> , 2021, 62, 2130-2140.	0.6	9
15	Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2021, 13, 2993.	1.7	9
16	Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. <i>Blood Advances</i> , 2021, 5, 5588-5598.	2.5	24
17	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 1886.	1.6	25
18	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1928365.	2.1	6

#	ARTICLE	IF	CITATIONS
19	Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. <i>Blood</i> , 2021, 138, 2395-2395.	0.6	1
20	Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor- $\kappa$ B and nuclear factor of activated T cells pathways. <i>British Journal of Dermatology</i> , 2020, 182, 147-155.	1.4	26
21	Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. <i>Pathology</i> , 2020, 52, 154-165.	0.3	58
22	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 657-664.	2.1	21
23	Update on peripheral T-cell lymphomas with T-helper phenotype: Are there too many subtypes?. <i>Seminars in Diagnostic Pathology</i> , 2020, 37, 24-31.	1.0	10
24	Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells. <i>American Journal of Dermatopathology</i> , 2020, 42, 360-363.	0.3	1
25	Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma. <i>Annals of Hematology</i> , 2020, 99, 391-393.	0.8	1
26	The presence of Merkel cell carcinoma polyomavirus is associated with a distinct phenotype in neoplastic Merkel cell carcinoma cells and their tissue microenvironment. <i>PLoS ONE</i> , 2020, 15, e0232517.	1.1	10
27	An analysis of genetic targets for guiding clinical management of follicular lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 1361-1372.	1.0	0
28	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	2.5	22
29	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	6.9	27
30	Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. <i>Blood Cancer Journal</i> , 2020, 10, 49.	2.8	31
31	Breast implant-associated Epstein-Barr virus-positive large B-cell lymphomas: a report of three cases. <i>Haematologica</i> , 2020, 105, e412-e414.	1.7	17
32	Epstein-Barr virus-associated large B-cell lymphoma transformation in marginal zone B-cell lymphoma: a series of four cases. <i>Histopathology</i> , 2020, 77, 112-122.	1.6	7
33	High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. <i>PLoS ONE</i> , 2020, 15, e0229743.	1.1	10
34	Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. <i>Scientific Reports</i> , 2020, 10, 6721.	1.6	5
35	Three monocytic neoplasms in a single patient. <i>Leukemia and Lymphoma</i> , 2020, 61, 2523-2526.	0.6	3
36	Splenic Marginal Zone Lymphoma. <i>Encyclopedia of Pathology</i> , 2020, , 474-479.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?. <i>PLoS ONE</i> , 2020, 15, e0241634.	1.1	5
38	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. <i>American Journal of Clinical Pathology</i> , 2019, 152, 277-301.	0.4	6
39	Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma. <i>Annals of Hematology</i> , 2019, 98, 2837-2839.	0.8	0
40	Large cells with CD30 expression and Hodgkin-like features in primary cutaneous marginal zone B-cell lymphoma: a study of 13 cases. <i>European Journal of Cancer</i> , 2019, 119, S23.	1.3	0
41	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
42	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	2.9	39
43	Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia. <i>Scientific Reports</i> , 2019, 9, 975.	1.6	8
44	Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 34.	2.8	23
45	The Spectrum of EBV-Positive Mucocutaneous Ulcer. <i>American Journal of Surgical Pathology</i> , 2019, 43, 201-210.	2.1	41
46	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	1.6	106
47	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2019, 14, e0212813.	1.1	31
48	Large Cells With CD30 Expression and Hodgkin-like Features in Primary Cutaneous Marginal Zone B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1191-1202.	2.1	11
49	Atypical Histiocytic Lesion Preceding a Peripheral T-Cell Lymphoma Involving the Skin Exhibiting the Same Molecular Alterations. <i>American Journal of Dermatopathology</i> , 2019, 41, 148-154.	0.3	2
50	Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?. <i>American Journal of Dermatopathology</i> , 2019, 41, 846-850.	0.3	7
51	CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. <i>Haematologica</i> , 2019, 104, 226-235.	1.7	38
52	DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers. <i>Haematologica</i> , 2019, 104, e158-e162.	1.7	28
53	Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. <i>Journal of Pathology</i> , 2019, 247, 416-421.	2.1	25
54	MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. <i>Blood</i> , 2019, 134, 5092-5092.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. <i>Blood</i> , 2019, 134, 468-468.	0.6	8
56	Abstract 4725: Efficacy of a new small-molecule inhibitor of histone deacetylase 6 (HDAC6) in preclinical models of B-cell lymphoma and acute myeloid leukemia. , 2019, , .		0
57	Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , 2018, 245, 61-73.	2.1	24
58	Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis. <i>Leukemia</i> , 2018, 32, 1822-1826.	3.3	10
59	Castleman Disease and Rosai-Dorfman Disease. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 44-53.	1.0	15
60	Re-Defining "Reactive" lymphadenopathies: How molecular lessons have changed our minds. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 1-3.	1.0	0
61	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363.	3.3	36
62	Mutual regulation between BCL6 and a specific set of miRNAs controls T <sub>FH</sub> phenotype in peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 587-590.	1.2	6
63	Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 497-501.	1.2	17
64	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. <i>Oncotarget</i> , 2018, 9, 30869-30882.	0.8	9
65	Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. <i>Oncotarget</i> , 2018, 9, 16124-16133.	0.8	30
66	Updates from the central pathology review in patients with advanced stage mycosis fungoides (MF) and Sezary syndrome (SS) for the Global PROCLIP study. <i>European Journal of Cancer</i> , 2018, 101, S16-S17.	1.3	0
67	Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis. <i>American Journal of Clinical Pathology</i> , 2018, 150, 310-317.	0.4	10
68	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	2.3	64
69	Mycosis fungoides progression could be regulated by microRNAs. <i>PLoS ONE</i> , 2018, 13, e0198477.	1.1	14
70	<i>In vitro</i> and <i>in vivo</i> activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. <i>Haematologica</i> , 2018, 103, e537-e540.	1.7	15
71	Alteraciones moleculares en leucemia mieloide aguda y sus implicaciones clínicas y terapéuticas. <i>Medicina Clínica</i> , 2018, 151, 362-367.	0.3	21
72	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population. <i>Blood</i> , 2018, 132, 2938-2938.	0.6	0
74	Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines. <i>Blood</i> , 2018, 132, 2851-2851.	0.6	0
75	Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5383-5383.	0.6	0
76	pâ€œscp>MAPK</scp>1 expression associated with poor prognosis in angioimmunoblastic Tâ€œcell lymphoma patients. <i>British Journal of Haematology</i> , 2017, 176, 661-664.	1.2	2
77	B-cell lymphoblastic lymphoma presenting as solitary temporal mass with amplification of AML1/RUNX1: case report. <i>Hematological Oncology</i> , 2017, 35, 380-384.	0.8	1
78	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 764-769.	3.3	100
79	Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. <i>Blood</i> , 2017, 129, 1042-1045.	0.6	52
80	Splenic marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 56-64.	0.7	33
81	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	1.9	39
82	Clinical and diagnostic relevance of <i>NOTCH2</i> -and <i>KLF2</i> -mutations in splenic marginal zone lymphoma. <i>Haematologica</i> , 2017, 102, e310-e312.	1.7	31
83	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , 2017, 117, 1685-1688.	2.9	13
84	Targeting the T cell receptor Î²-chain constant region for immunotherapy of T cell malignancies. <i>Nature Medicine</i> , 2017, 23, 1416-1423.	15.2	196
85	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. <i>Leukemia</i> , 2017, 31, 625-636.	3.3	47
86	Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. <i>Modern Pathology</i> , 2017, 30, 85-94.	2.9	63
87	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 2017, 137, 197-206.	0.3	78
88	Mutational profile of primary breast diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 102888-102897.	0.8	22
89	Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines. <i>PLoS ONE</i> , 2017, 12, e0177524.	1.1	4
90	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. <i>Oncotarget</i> , 2017, 8, 111386-111395.	0.8	33

#	ARTICLE	IF	CITATIONS
91	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	0.8	93
92	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. <i>Oncotarget</i> , 2016, 7, 18036-18049.	0.8	26
93	CD30 Expression by B and T Cells. <i>American Journal of Surgical Pathology</i> , 2016, 40, 378-385.	2.1	37
94	Incidental and Isolated Follicular Lymphoma In Situ and Mantle Cell Lymphoma In Situ Lack Clinical Significance. <i>American Journal of Surgical Pathology</i> , 2016, 40, 943-949.	2.1	30
95	Primary cutaneous follicular helper T cell lymphoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 164-170.	0.7	9
96	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	0.6	59
97	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	3.2	48
98	Nodal marginal zone mutational signature. <i>Blood</i> , 2016, 128, 1315-1316.	0.6	0
99	C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. <i>Haematologica</i> , 2016, 101, e336-e338.	1.7	25
100	Angioimmunoblastic T cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1203-1210.	0.7	7
101	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , 2016, 127, 221-232.	0.6	97
102	An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. <i>Clinical Cancer Research</i> , 2016, 22, 2032-2040.	3.2	17
103	Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 411-421.	1.1	14
104	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. <i>Leukemia</i> , 2016, 30, 361-372.	3.3	55
105	Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. <i>Leukemia</i> , 2016, 30, 94-103.	3.3	27
106	Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets. <i>Leukemia and Lymphoma</i> , 2016, 57, 134-142.	0.6	3
107	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	1.4	19
108	RelA NF- $\kappa$ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	1.4	29

#	ARTICLE	IF	CITATIONS
109	Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S220-S221.	0.2	0
110	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S228.	0.2	0
111	MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S223.	0.2	0
112	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	0.6	53
113	Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation. <i>Haematologica</i> , 2015, 100, e200-e203.	1.7	21
114	Nuclear coexpression of NF- $\kappa$ B subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S224.	0.2	0
115	Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features. <i>Histopathology</i> , 2015, 66, 846-855.	1.6	50
116	CD 30-positive transformed follicular lymphoma: two case reports and literature review. <i>Histopathology</i> , 2015, 67, 918-922.	1.6	3
117	Localized lymphomatoid papulosis. <i>International Journal of Dermatology</i> , 2015, 54, e98-100.	0.5	3
118	MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 644-651.	2.1	76
119	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614.	0.8	61
120	Colorectal Adenomas Contain Multiple Somatic Mutations That Do Not Coincide with Synchronous Adenocarcinoma Specimens. <i>PLoS ONE</i> , 2015, 10, e0119946.	1.1	11
121	Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. <i>Haematologica</i> , 2015, 100, 1460-1468.	1.7	19
122	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 744.	7.7	2
123	Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Cancer Treatment Communications</i> , 2015, 4, S1-S11.	0.4	1
124	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , 2015, 29, 1390-1401.	3.3	42
125	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	7.7	378
126	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	2.9	48



#	ARTICLE	IF	CITATIONS
127	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	2.9	21
128	Evaluation of NF- $\kappa$ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	2.9	17
129	Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S216.	0.2	1
130	Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. <i>British Journal of Haematology</i> , 2015, 169, 188-198.	1.2	49
131	Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. <i>Haematologica</i> , 2015, 100, e25-e27.	1.7	37
132	Unique Versus Common: Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations. <i>Blood</i> , 2015, 126, 1479-1479.	0.6	2
133	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0125203.	1.1	30
134	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	0.8	72
135	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	0.8	35
136	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	0.8	33
137	Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. <i>Haematologica</i> , 2015, 100, e450-e453.	1.7	59
138	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. <i>Oncotarget</i> , 2015, 6, 25452-25465.	0.8	3
139	Analysis of the Genomic Heterogeneity in Hodgkin Lymphoma Using Next Generation Sequencing. <i>Blood</i> , 2015, 126, 178-178.	0.6	0
140	PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. <i>PLoS ONE</i> , 2014, 9, e112148.	1.1	18
141	FAS system deregulation in T-cell lymphoblastic lymphoma. <i>Cell Death and Disease</i> , 2014, 5, e1110-e1110.	2.7	15
142	Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma. <i>Leukemia</i> , 2014, 28, 1103-1112.	3.3	60
143	NF- $\kappa$ B expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2014, 27, 1331-1337.	2.9	27
144	Adult pityriasis lichenoides-like mycosis fungoides: a clinical variant of mycosis fungoides. <i>International Journal of Dermatology</i> , 2014, 53, 1331-1338.	0.5	12

#	ARTICLE	IF	CITATIONS
145	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S146-S147.	0.2	0
146	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries: A report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S144-S145.	0.2	0
147	NF- $\kappa$ B directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas. <i>Nucleic Acids Research</i> , 2014, 42, 11025-11039.	6.5	27
148	Childhood florid follicular hyperplasia with immunoglobulin light chain restriction in the gastrointestinal tract. <i>Histopathology</i> , 2014, 65, 805-813.	1.6	4
149	Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. <i>Leukemia and Lymphoma</i> , 2014, 55, 929-931.	0.6	40
150	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia</i> , 2014, 28, 823-829.	3.3	148
151	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. <i>Nature Genetics</i> , 2014, 46, 166-170.	9.4	534
152	HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases. <i>British Journal of Haematology</i> , 2014, 165, 580-581.	1.2	10
153	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	3.2	117
154	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. <i>Haematologica</i> , 2014, 99, 222-231.	1.7	52
155	Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study. <i>Modern Pathology</i> , 2014, 27, 281-293.	2.9	22
156	The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. <i>Blood</i> , 2014, 123, 2893-2894.	0.6	53
157	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	2.9	112
158	The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma. <i>Infectious Agents and Cancer</i> , 2014, 9, 12.	1.2	55
159	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	3.2	60
160	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	2.0	32
161	Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. <i>Leukemia</i> , 2014, 28, 1334-1340.	3.3	115
162	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , 2014, 99, e138-e141.	1.7	2

#	ARTICLE	IF	CITATIONS
163	PLCG1 mutations in cutaneous T-cell lymphomas. <i>Blood</i> , 2014, 123, 2034-2043.	0.6	193
164	miR-217 is an oncogene that enhances the germinal center reaction. <i>Blood</i> , 2014, 124, 229-239.	0.6	57
165	An A91V SNP in the Perforin Gene Is Frequently Found in NK/T-Cell Lymphomas. <i>PLoS ONE</i> , 2014, 9, e91521.	1.1	13
166	High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. <i>Oncotarget</i> , 2014, 5, 4694-4708.	0.8	22
167	Abstract 4202: Deciphering the effects of GNA13 mutations in B-cell lymphomas. , 2014, , .		0
168	NF- $\kappa$ B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 1620-1620.	0.6	0
169	I. Pathological and clinical diversity in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2013, 31, 23-25.	0.8	3
170	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , 2013, 122, 2683-2693.	0.6	98
171	MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 336-347.	1.2	39
172	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013, 122, 2673-2682.	0.6	208
173	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
174	BCL7A protein expression in normal and malignant lymphoid tissues. <i>British Journal of Haematology</i> , 2013, 160, 106-109.	1.2	9
175	Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. <i>Modern Pathology</i> , 2013, 26, 889-901.	2.9	45
176	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
177	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	1.7	142
178	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. <i>Modern Pathology</i> , 2013, 26, 171-181.	2.9	19
179	Down-regulation of specific miRNAs enhances the expression of the gene Smoothed and contributes to T-cell lymphoblastic lymphoma development. <i>Carcinogenesis</i> , 2013, 34, 902-908.	1.3	27
180	NIK Controls Classical and Alternative NF- $\kappa$ B Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells. <i>Clinical Cancer Research</i> , 2013, 19, 2319-2330.	3.2	52

#	ARTICLE	IF	CITATIONS
181	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2013, 66, 956-961.	1.0	24
182	Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. <i>Blood Cancer Journal</i> , 2013, 3, e111-e111.	2.8	19
183	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 2630-2640.	0.6	46
184	SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. <i>Blood</i> , 2013, 121, 643-647.	0.6	47
185	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540.	0.6	41
186	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 122, 2233-2241.	0.6	45
187	Cutaneous EBV-associated lymphoma?. <i>Blood</i> , 2013, 122, 3095-3095.	0.6	1
188	Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, 57-64.	1.7	33
189	TCR-β Expression in Primary Cutaneous T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 375-384.	2.1	122
190	Persistent Polyclonal B-cell Lymphocytosis With Splenomegaly. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1085-1090.	2.1	3
191	Activating Mutations In Fyn Kinase In Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 811-811.	0.6	3
192	Abstract 3533: Clinical impact of NF-KB activation in diffuse large B cell lymphoma.. , 2013, , .		0
193	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 363-363.	0.6	0
194	Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. <i>Leukemia and Lymphoma</i> , 2012, 53, 185-194.	0.6	53
195	Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. <i>Leukemia and Lymphoma</i> , 2012, 53, 812-819.	0.6	14
196	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-κB activation. <i>Modern Pathology</i> , 2012, 25, 968-982.	2.9	172
197	Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. <i>Leukemia</i> , 2012, 26, 1638-1646.	3.3	108
198	E2F4 plays a key role in Burkitt lymphoma tumorigenesis. <i>Leukemia</i> , 2012, 26, 2277-2285.	3.3	19

#	ARTICLE	IF	CITATIONS
199	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012, 23, 729-735.	0.6	19
200	Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. <i>Haematologica</i> , 2012, 97, 1080-1084.	1.7	56
201	Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. <i>Haematologica</i> , 2012, 97, 1614-1616.	1.7	13
202	Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. <i>Blood</i> , 2012, 120, 812-821.	0.6	40
203	Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. <i>British Journal of Haematology</i> , 2012, 159, 164-171.	1.2	81
204	High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 712-726.	1.2	45
205	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	0.6	301
206	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> , 2012, 26, 2103-2113.	3.3	301
207	Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2012, 26, 180-183.	3.3	50
208	Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. <i>Blood</i> , 2012, 119, e9-e21.	0.6	91
209	MicroRNA signatures in B-cell lymphomas. <i>Blood Cancer Journal</i> , 2012, 2, e57-e57.	2.8	79
210	The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. <i>Blood</i> , 2012, 120, 1782-1790.	0.6	68
211	New Mutations in Chronic Lymphocytic Leukemia Identified by Target Enrichment and Deep Sequencing. <i>PLoS ONE</i> , 2012, 7, e38158.	1.1	38
212	Clonal Selection in the Ontogeny and Evolution of Splenic Marginal Zone Lymphoma Confirming the Existence of Distinct Molecular Subtypes. <i>Blood</i> , 2012, 120, 1556-1556.	0.6	0
213	Mutational Status of Splenic Marginal Zone Lymphoma Revealed by Whole Exome Sequencing. <i>Blood</i> , 2012, 120, 2698-2698.	0.6	0
214	Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas. <i>Blood</i> , 2012, 120, 300-300.	0.6	0
215	Characterization of Subclonal Changes Along Progression in Multiple Myeloma. <i>Blood</i> , 2012, 120, 2924-2924.	0.6	1
216	Hairy cell leukemia, blastic type: description of spleen morphology and immunophenotype of a distinctive case. <i>Leukemia and Lymphoma</i> , 2011, 52, 1589-1592.	0.6	3

#	ARTICLE	IF	CITATIONS
217	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011, 475, 101-105.	13.7	1,364
218	Marginal zone lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 135-145.	1.0	15
219	The use of molecular profiling for diagnosis and research in non-Hodgkin's lymphoma. <i>Hematology Reports</i> , 2011, 3, e2.	0.3	0
220	Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas. <i>PLoS ONE</i> , 2011, 6, e24939.	1.1	23
221	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
222	Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. <i>Blood</i> , 2011, 117, 6255-6266.	0.6	60
223	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. <i>Blood</i> , 2011, 118, 1034-1040.	0.6	90
224	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. <i>Blood</i> , 2011, 118, 5517-5527.	0.6	83
225	HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. <i>British Journal of Haematology</i> , 2011, 152, 352-356.	1.2	10
226	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011, 153, 499-503.	1.2	12
227	Early phase of Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma of the elderly mimicking EBV-positive reactive follicular hyperplasia. <i>Histopathology</i> , 2011, 59, 571-575.	1.6	10
228	Epstein-Barr virus-positive systemic NK/T-cell lymphomas in children: report of six cases. <i>Histopathology</i> , 2011, 59, 1183-1193.	1.6	30
229	Hairy cell leukemia variant. <i>Journal of Hematopathology</i> , 2011, 4, 13-16.	0.2	2
230	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011, 29, 38-41.	0.8	29
231	Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. <i>Modern Pathology</i> , 2011, 24, 698-707.	2.9	9
232	A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12461-12466.	3.3	50
233	Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System. <i>Blood</i> , 2011, 118, 1583-1583.	0.6	1
234	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011, 118, 949-949.	0.6	3

#	ARTICLE	IF	CITATIONS
235	PIM Kinases Inhibition, a Rational Strategy in Peripheral T-Cell Lymphomas,. Blood, 2011, 118, 3494-3494.	0.6	0
236	The NF- $\kappa$ B-Inducing Kinase (NIK) Is Involved in Both Classical and Alternative NF- $\kappa$ B Activation and Is Necessary for the Survival of T Cell Lymphoma Cells,. Blood, 2011, 118, 3665-3665.	0.6	0
237	Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?. Blood, 2011, 118, 2638-2638.	0.6	0
238	PI3K Inhibition As a Potential Therapeutic Strategy in Peripheral T-Cell Lymphomas,. Blood, 2011, 118, 3493-3493.	0.6	0
239	The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica, 2010, 95, 432-439.	1.7	99
240	EBV-associated Cutaneous NK/T-cell Lymphoma. American Journal of Surgical Pathology, 2010, 34, 1773-1782.	2.1	106
241	Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica, 2010, 95, 1122-1129.	1.7	79
242	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood, 2010, 116, 1479-1488.	0.6	174
243	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood, 2010, 116, e12-e17.	0.6	47
244	Polycomb proteins in hematologic malignancies. Blood, 2010, 116, 5465-5475.	0.6	56
245	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. Haematologica, 2010, 95, 2056-2062.	1.7	28
246	Genomic profiling of Richter's syndrome: recurrent lesions and differences with <i>de novo</i> diffuse large B-cell lymphomas. Hematological Oncology, 2010, 28, 62-67.	0.8	46
247	Intrafollicular neoplasia/in situ follicular lymphoma: review of a series of 13 cases. Histopathology, 2010, 56, 658-662.	1.6	66
248	Genome wide DNA-profiling of HIV-related B-cell lymphomas. British Journal of Haematology, 2010, 148, 245-255.	1.2	70
249	Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. British Journal of Haematology, 2010, 149, 569-577.	1.2	53
250	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21. British Journal of Haematology, 2010, 151, 221-231.	1.2	47
251	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	1.2	20
252	Proliferation centers in chronic lymphocytic leukemia: the niche where NF- $\kappa$ B activation takes place. Leukemia, 2010, 24, 872-876.	3.3	34

#	ARTICLE	IF	CITATIONS
253	Mantle cell lymphoma: transcriptional regulation by microRNAs. <i>Leukemia</i> , 2010, 24, 1335-1342.	3.3	72
254	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	13.7	2,114
255	Cutaneous T-Cell Lymphoma: Two Faces of the Same Coin. <i>Journal of Investigative Dermatology</i> , 2010, 130, 348-351.	0.3	6
256	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. <i>Haematologica</i> , 2010, 95, 1342-1349.	1.7	128
257	Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. <i>Haematologica</i> , 2010, 95, 613-621.	1.7	93
258	miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. <i>Cell Cycle</i> , 2010, 9, 3297-3305.	1.3	102
259	Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2010, 177, 930-942.	1.9	41
260	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. <i>Cancer Research</i> , 2010, 70, 1408-1418.	0.4	429
261	Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglobulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells. <i>Blood</i> , 2010, 116, 634-634.	0.6	2
262	NIK Is Involved In the Activation of the Classical and Alternative NF- $\kappa$ B Pathways In Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2010, 116, 3099-3099.	0.6	1
263	A Novel Pro-Survival Function of Cyclin-D1 Underlies Its Oncogenic Role and Potential as a Therapeutic Target In Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 769-769.	0.6	0
264	Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples. <i>Blood</i> , 2010, 116, 2470-2470.	0.6	0
265	Mirna EXPRESSION SIGNATURES as PROGNOSTIC Markers IN ADVANCED Classical HODGKIN LYMPHOMA. <i>Blood</i> , 2010, 116, 4157-4157.	0.6	1
266	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. <i>Genome Research</i> , 2009, 19, 438-451.	2.4	218
267	Expression pattern of XBP1(S) in human B-cell lymphomas. <i>Haematologica</i> , 2009, 94, 419-422.	1.7	27
268	A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples. <i>Clinical Cancer Research</i> , 2009, 15, 1367-1375.	3.2	36
269	<i>E2F1</i> Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma. <i>Cancer Research</i> , 2009, 69, 4052-4058.	0.4	39
270	Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells. <i>Cancer Cell</i> , 2009, 16, 103-114.	7.7	163



#	ARTICLE	IF	CITATIONS
271	Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. <i>Cancer</i> , 2009, 115, 3728-3737.	2.0	31
272	Follicular T-cell lymphoma: description of a case with characteristic findings suggesting it is a different condition from AITL. <i>Histopathology</i> , 2009, 54, 902-904.	1.6	7
273	Psoralen plus ultraviolet A interferon- $\gamma$ treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor- $\kappa$ B and T-cell receptor pathways. <i>British Journal of Dermatology</i> , 2009, 160, 92-102.	1.4	22
274	Cancer induction by restriction of oncogene expression to the stem cell compartment. <i>EMBO Journal</i> , 2009, 28, 8-20.	3.5	125
275	Identification of MNDA as a new marker for nodal marginal zone lymphoma. <i>Leukemia</i> , 2009, 23, 1847-1857.	3.3	87
276	Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. <i>Modern Pathology</i> , 2009, 22, 753-761.	2.9	65
277	Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers. <i>Modern Pathology</i> , 2009, 22, 1006-1015.	2.9	78
278	Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. <i>Leukemia and Lymphoma</i> , 2009, 50, 1699-1708.	0.6	10
279	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. <i>Clinical Cancer Research</i> , 2009, 15, 5494-5502.	3.2	577
280	Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 571-581.	0.6	7
281	TCL1A expression delineates biological and clinical variability in B-cell lymphoma. <i>Modern Pathology</i> , 2009, 22, 206-215.	2.9	46
282	Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers. <i>American Journal of Surgical Pathology</i> , 2009, 33, 81-90.	2.1	226
283	Splenic Follicular Lymphoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 730-738.	2.1	41
284	Integrative Analysis of MicroRNA and Gene Expression Profiling Contributes to Understand Mantle Cell Lymphoma Pathogenesis.. <i>Blood</i> , 2009, 114, 2936-2936.	0.6	5
285	Molecular Heterogeneity as a Basis for Rational Therapeutics in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 2348-2348.	0.6	0
286	BCL6 represses NF $\kappa$ B activity in diffuse large B-cell lymphomas. <i>Journal of Pathology</i> , 2008, 214, 498-507.	2.1	37
287	Transcriptomal profiling of the cellular response to DNA damage mediated by Slug (Snai2). <i>British Journal of Cancer</i> , 2008, 98, 480-488.	2.9	18
288	Lymphoma microenvironment: culprit or innocent?. <i>Leukemia</i> , 2008, 22, 49-58.	3.3	63

#	ARTICLE	IF	CITATIONS
289	The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. <i>Leukemia</i> , 2008, 22, 1268-1272.	3.3	40
290	Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. <i>Leukemia</i> , 2008, 22, 487-495.	3.3	244
291	Light chain restricted germinal centres in reactive lymphadenitis: report of eight cases. <i>Histopathology</i> , 2008, 52, 436-444.	1.6	40
292	Primary mediastinal B-cell lymphoma: Treatment and therapeutic targets. <i>Leukemia and Lymphoma</i> , 2008, 49, 1050-1061.	0.6	15
293	Frequency of <i>BCL2</i> and <i>BCL6</i> translocations in follicular lymphoma: Relation with histological and clinical features. <i>Leukemia and Lymphoma</i> , 2008, 49, 95-101.	0.6	42
294	Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. <i>Haematologica</i> , 2008, 93, 670-679.	1.7	77
295	<i>Gcet1</i> (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. <i>Blood</i> , 2008, 111, 351-358.	0.6	69
296	Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways. <i>Blood</i> , 2008, 111, 1665-1676.	0.6	17
297	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173
298	Peripheral T-cell Lymphoma With Follicular T-cell Markers. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1787-1799.	2.1	115
299	Somatic hypermutation signature in B-cell low-grade lymphomas. <i>Haematologica</i> , 2008, 93, 1186-1194.	1.7	11
300	PD-1, a Follicular T-cell Marker Useful for Recognizing Nodular Lymphocyte-predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1252-1257.	2.1	122
301	Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and Mouse Models of Mantle Cell Lymphoma. <i>Blood</i> , 2008, 112, 608-608.	0.6	1
302	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008, 112, 478-478.	0.6	0
303	A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis. <i>Cancer Research</i> , 2007, 67, 3450-3460.	0.4	274
304	Thymoma and progressive T-cell lymphocytosis. <i>Annals of Oncology</i> , 2007, 18, 603-604.	0.6	7
305	KSHV- and EBV-associated germinotropic lymphoproliferative disorder: A rare lymphoproliferative disease of HIV patient with plasmablastic morphology, indolent course and favourable response to therapy. <i>Leukemia and Lymphoma</i> , 2007, 48, 1444-1447.	0.6	24
306	Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. <i>Haematologica</i> , 2007, 92, 1059-1066.	1.7	142

#	ARTICLE	IF	CITATIONS
307	Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. <i>Journal of Cellular Biochemistry</i> , 2007, 100, 339-348.	1.2	39
308	Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. <i>Leukemia</i> , 2007, 21, 1984-1991.	3.3	52
309	MicroRNA losses in the frequently deleted region of 7q in SMZL. <i>Leukemia</i> , 2007, 21, 2547-2549.	3.3	50
310	The BCL6 Oncogene Drives an Epigenomic Program Linking Stem Cells to the Pathogenesis of Human Diffuse Large B Cell Lymphoma in Mice.. <i>Blood</i> , 2007, 110, 3372-3372.	0.6	0
311	Mycosis Fungoide: Immunochemistry Analysis of Lymphoid and Microenvironment Cells by Macrotissue Array.. <i>Blood</i> , 2007, 110, 4400-4400.	0.6	0
312	Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. <i>Leukemia</i> , 2006, 20, 1047-1054.	3.3	95
313	Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. <i>Genomics</i> , 2006, 87, 113-118.	1.3	34
314	Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. <i>Blood</i> , 2006, 108, 662-668.	0.6	131
315	Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. <i>Histopathology</i> , 2006, 48, 481-504.	1.6	77
316	Evolving concepts in the pathogenesis of hairy-cell leukaemia. <i>Nature Reviews Cancer</i> , 2006, 6, 437-448.	12.8	90
317	Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. <i>Modern Pathology</i> , 2006, 19, 684-694.	2.9	83
318	Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. <i>Modern Pathology</i> , 2006, 19, 1055-1067.	2.9	29
319	Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. <i>Oncogene</i> , 2006, 25, 2565-2574.	2.6	21
320	The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. <i>Cancer Cell</i> , 2006, 9, 301-312.	7.7	299
321	Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis. <i>Cancer Research</i> , 2006, 66, 5744-5756.	0.4	127
322	Transcriptome Classification of B-Cell Non-Hodgkins Lymphoma.. <i>Blood</i> , 2006, 108, 819-819.	0.6	0
323	Splenic Marginal Zone Lymphoma Shows a Distinct Pattern of DNA Copy Number Aberrations That Correlates with Tumor Characteristics and Predicts Disease Outcome.. <i>Blood</i> , 2006, 108, 2422-2422.	0.6	0
324	The Expression of T Cell Receptor Signaling Genes Is Associated with Poor Response to IFN- $\gamma$ and/or PUVA in Mycosis Fungoides.. <i>Blood</i> , 2006, 108, 2053-2053.	0.6	0

#	ARTICLE	IF	CITATIONS
325	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. <i>Haematologica</i> , 2006, 91, 467-74.	1.7	70
326	The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. <i>Haematologica</i> , 2006, 91, 1605-12.	1.7	77
327	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. <i>Blood</i> , 2005, 106, 1831-1838.	0.6	138
328	Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. <i>Blood</i> , 2005, 105, 4445-4454.	0.6	180
329	Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. <i>Histopathology</i> , 2005, 46, 241-255.	1.6	29
330	Large B-cell lymphoma with Hodgkin's features. <i>Histopathology</i> , 2005, 47, 101-110.	1.6	101
331	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. <i>Nature Genetics</i> , 2005, 37, 391-400.	9.4	1,710
332	FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. <i>Leukemia</i> , 2005, 19, 2247-2253.	3.3	131
333	Nodal and splenic marginal zone B cell lymphomas. <i>Hematological Oncology</i> , 2005, 23, 108-118.	0.8	54
334	Expression of the NF- $\kappa$ B targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. <i>Journal of Pathology</i> , 2005, 206, 123-134.	2.1	126
335	Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 814-823.	1.9	50
336	Inactivation of the Lamin A/C Gene by CpG Island Promoter Hypermethylation in Hematologic Malignancies, and Its Association With Poor Survival in Nodal Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3940-3947.	0.8	119
337	Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells. <i>Clinical Cancer Research</i> , 2005, 11, 1467-1473.	3.2	401
338	Identification of Surrogate Prognostic Markers and Genes Implicated in Immunoglobulin Gene (IgVH) Somatic Hypermutation in Small B-Cell Lymphomas.. <i>Blood</i> , 2005, 106, 1004-1004.	0.6	0
339	FOXP3 Expression in B and T Cell Lymphomas.. <i>Blood</i> , 2005, 106, 4503-4503.	0.6	0
340	Variability in the Degree of Expression of Phosphorylated I $\kappa$ B $\beta$ in Chronic Lymphocytic Leukemia Cases With Nodal Involvement. <i>Clinical Cancer Research</i> , 2004, 10, 6796-6806.	3.2	35
341	Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 1664-1673.	0.8	60
342	Transcriptional Response of T Cells to IFN- $\gamma$ : Changes Induced in IFN- $\gamma$ -Sensitive and Resistant Cutaneous T Cell Lymphoma. <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 185-195.	0.5	23

#	ARTICLE	IF	CITATIONS
343	Overexpression of human DNA polymerase $\hat{A}$ (Pol $\hat{A}$ ) in a Burkitt's lymphoma cell line affects the somatic hypermutation rate. <i>Nucleic Acids Research</i> , 2004, 32, 5861-5873.	6.5	35
344	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the $\hat{a}$ cutaneous variant <sup>TM</sup> 1. <i>British Journal of Haematology</i> , 2004, 127, 173-183.	1.2	535
345	IgVH and bcl6 somatic mutation analysis reveals the heterogeneity of cutaneous B-cell lymphoma, and indicates the presence of undisclosed local antigens. <i>Modern Pathology</i> , 2004, 17, 623-630.	2.9	8
346	Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NF $\hat{B}$ transcription factors. <i>Journal of Pathology</i> , 2004, 204, 528-537.	2.1	63
347	Posible implicaci3n de las alteraciones moleculares de la vAa de TNF en la tumorig3nesis de la micosis fungoide. Descripci3n de un posible chip de diagn3stico molecular en micosis fungoide. <i>Actas Dermo-sifiliogr3ficas</i> , 2004, 95, 86-96.	0.2	2
348	Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles. <i>American Journal of Pathology</i> , 2004, 164, 193-203.	1.9	226
349	Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 613-622.	1.9	87
350	Aberrant Bcl6 Protein Expression in Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1051-1056.	2.1	55
351	Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. <i>Blood</i> , 2004, 103, 2351-2357.	0.6	60
352	Follicular Lymphoma: Design of a Protein-Based Survival Predictor Using Tissue-Microarrays (TMA).. <i>Blood</i> , 2004, 104, 2266-2266.	0.6	0
353	Mantle Cell Lymphoma Genotypes Identified with CGH to BAC Microarrays Define Clinical Subgroups of Disease and Strongly Predict Patient Outcome.. <i>Blood</i> , 2004, 104, 695-695.	0.6	0
354	Cytogenetic and FISH Study of 92 Patients with Splenic Marginal Zone B-Cell Lymphoma (SMZBCL).. <i>Blood</i> , 2004, 104, 699-699.	0.6	0
355	Clinical and Biological Relevance of NF- $\hat{B}$ Activation in B-CLL.. <i>Blood</i> , 2004, 104, 2792-2792.	0.6	0
356	Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. <i>Leukemia</i> , 2003, 17, 2016-2024.	3.3	76
357	Development of a Real-Time Reverse Transcription Polymerase Chain Reaction Assay for c-myc Expression That Allows the Identification of a Subset of c-myc+ Diffuse Large B-Cell Lymphoma. <i>Laboratory Investigation</i> , 2003, 83, 143-152.	1.7	17
358	Cell cycle deregulation in B-cell lymphomas. <i>Blood</i> , 2003, 101, 1220-1235.	0.6	329
359	Nodal Marginal Zone Lymphoma: A Heterogeneous Tumor. <i>American Journal of Surgical Pathology</i> , 2003, 27, 762-771.	2.1	106
360	Composite Hodgkin Lymphoma and Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1577-1580.	2.1	49

#	ARTICLE	IF	CITATIONS
361	Large B-cell Lymphoma Presenting in the Spleen. American Journal of Surgical Pathology, 2003, 27, 895-902.	2.1	50
362	Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood, 2003, 101, 681-689.	0.6	224
363	Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood, 2003, 102, 1042-1050.	0.6	153
364	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046.	0.6	121
365	The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research, 2003, 63, 8226-32.	0.4	130
366	Analysis of Octamer-Binding Transcription Factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in Lymphomas. Modern Pathology, 2002, 15, 211-220.	2.9	62
367	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2002, 10, 7-14.	2.0	44
368	Hydroa-Like Cutaneous T-Cell Lymphoma: A Clinicopathologic and Molecular Genetic Study of 16 Pediatric Cases from Peru. Applied Immunohistochemistry and Molecular Morphology, 2002, 10, 7-14.	0.6	116
369	Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 2002, 99, 1299-1304.	0.6	158
370	p14ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood, 2002, 99, 1411-1418.	0.6	53
371	A Short Mutational Hot Spot in the First Intron of BCL-6 Is Associated with Increased BCL-6 Expression and with Longer Overall Survival in Large B-Cell Lymphomas. American Journal of Pathology, 2002, 160, 1371-1380.	1.9	47
372	Identification of Genes Involved in Resistance to Interferon- $\gamma$ in Cutaneous T-Cell Lymphoma. American Journal of Pathology, 2002, 161, 1825-1837.	1.9	106
373	Nucleolar p14ARF Overexpression in Reed-Sternberg Cells in Hodgkin's Lymphoma. American Journal of Pathology, 2002, 160, 569-578.	1.9	16
374	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100, 1648-1654.	0.6	184
375	Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma?. Histopathology, 2002, 40, 22-30.	1.6	70
376	Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology, 2002, 41, 1-29.	1.6	576
377	T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology, 2002, 41, 216-229.	1.6	56
378	p16INK4a Is Selectively Silenced in the Tumoral Progression of Mycosis Fungoides. Laboratory Investigation, 2002, 82, 123-132.	1.7	47

#	ARTICLE	IF	CITATIONS
379	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. <i>Blood</i> , 2002, 100, 1648-54.	0.6	45
380	Overall Survival in Aggressive B-Cell Lymphomas Is Dependent on the Accumulation of Alterations in p53, p16, and p27. <i>American Journal of Pathology</i> , 2001, 159, 205-213.	1.9	68
381	Unique Phenotypic Profile of Monocytoid B Cells. <i>American Journal of Pathology</i> , 2001, 158, 1363-1369.	1.9	27
382	Novel Genomic Imbalances in B-Cell Splenic Marginal Zone Lymphomas Revealed by Comparative Genomic Hybridization and Cytogenetics. <i>American Journal of Pathology</i> , 2001, 158, 1843-1850.	1.9	88
383	Primary Cutaneous Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2001, 25, 307-315.	2.1	43
384	Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1268-1276.	2.1	126
385	Cutaneous Follicular B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2001, 25, 875-883.	2.1	82
386	Cutaneous Presentation of Follicular Lymphomas. <i>Modern Pathology</i> , 2001, 14, 913-919.	2.9	29
387	p16INK4a Gene Alterations Are Frequent in Lesions of Mycosis Fungoides. <i>American Journal of Pathology</i> , 2000, 156, 1565-1572.	1.9	94
388	Epstein-Barr Virus-Latent Membrane Protein 1 Expression Has a Favorable Influence in the Outcome of Patients with Hodgkin's Disease Treated with Chemotherapy. <i>Leukemia and Lymphoma</i> , 2000, 39, 563-572.	0.6	39
389	Anomalous High p27/KIP1 Expression in a Subset of Aggressive B-Cell Lymphomas Is Associated With Cyclin D3 Overexpression. p27/KIP1 and Cyclin D3 Colocalization in Tumor Cells. <i>Blood</i> , 1999, 94, 765-772.	0.6	105
390	p27KIP1 is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome. <i>British Journal of Cancer</i> , 1999, 80, 1427-1434.	2.9	40
391	Splenic marginal zone lymphoma with increased number of blasts: An aggressive variant?. <i>Human Pathology</i> , 1999, 30, 1153-1160.	1.1	50
392	7q31-32 Allelic Loss Is a Frequent Finding in Splenic Marginal Zone Lymphoma. <i>American Journal of Pathology</i> , 1999, 154, 1583-1589.	1.9	154
393	Other Cancers in Patients with Gastric Malt Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 33, 161-168.	0.6	33
394	Anomalous High p27/KIP1 Expression in a Subset of Aggressive B-Cell Lymphomas Is Associated With Cyclin D3 Overexpression. p27/KIP1 and Cyclin D3 Colocalization in Tumor Cells. <i>Blood</i> , 1999, 94, 765-772.	0.6	2
395	Mantle cell lymphoma. , 1998, 82, 567-575.		302
396	A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma. <i>Histopathology</i> , 1998, 33, 230-239.	1.6	67

#	ARTICLE	IF	CITATIONS
397	Crystal-storing histiocytosis and immunocytoma associated with multifocal fibrosclerosis. <i>Histopathology</i> , 1998, 33, 459-464.	1.6	51
398	Loss of p16/INK4A Protein Expression in Non-Hodgkin's Lymphomas Is a Frequent Finding Associated with Tumor Progression. <i>American Journal of Pathology</i> , 1998, 153, 887-897.	1.9	111
399	Splenic Marginal Zone Lymphoma. <i>Advances in Anatomic Pathology</i> , 1997, 4, 191-201.	2.4	25
400	Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone B-cell lymphoma. <i>British Journal of Haematology</i> , 1997, 98, 446-449.	1.2	56
401	Lymph Node Involvement by Splenic Marginal Zone Lymphoma: Morphological and Immunohistochemical Features. <i>American Journal of Surgical Pathology</i> , 1997, 21, 772-780.	2.1	51
402	Detection of the <i>bcl-1</i> Rearrangement at the Major Translocation Cluster in Frozen and Paraffin-Embedded Tissues of Mantle Cell Lymphomas by Polymerase Chain Reaction. <i>American Journal of Clinical Pathology</i> , 1996, 105, 532-537.	0.4	44
403	MDM2 AND p21WAF1/CIP1, WILD-TYPE p53-INDUCED PROTEINS, ARE REGULARLY EXPRESSED BY STERNBERG-REED CELLS IN HODGKIN'S DISEASE. , 1996, 180, 58-64.		23
404	EBV-positive non-Hodgkin's lymphoma developing after phenytoin therapy. <i>British Journal of Haematology</i> , 1996, 95, 376-379.	1.2	3
405	Evaluation of the International Index in the Prognosis of High Grade Gastric Malt Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 24, 159-163.	0.6	13
406	True Histiocytic Lymphoma of the Stomach Associated with Low-grade B-cell Mucosa-associated Lymphoid Tissue (Malt)-type Lymphoma. <i>American Journal of Surgical Pathology</i> , 1996, 20, 1406-1411.	2.1	43
407	MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. <i>Journal of Pathology</i> , 1995, 177, 27-34.	2.1	33
408	p53 Expression in Non-Hodgkin's Lymphomas: A Marker of p53 Inactivation?. <i>Leukemia and Lymphoma</i> , 1995, 17, 35-42.	0.6	23
409	Tumour Suppressor Genes in Hodgkin's Disease. , 1995, , 209-222.		0
410	p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. <i>British Journal of Cancer</i> , 1994, 69, 337-341.	2.9	173
411	Monocytoid B Cells. <i>American Journal of Surgical Pathology</i> , 1994, 18, 1131-1139.	2.1	35
412			



#	ARTICLE	IF	CITATIONS
415	Lennert's Lymphoma with Giant Multivesicular Lysosomal Bodies Optically Visible. <i>Ultrastructural Pathology</i> , 1992, 16, 283-290.	0.4	4
416	Gastric B-cell mucosa associated lymphoid tissue lymphoma: a clinicopathological study in 56 patients.. <i>Gut</i> , 1992, 33, 1307-1311.	6.1	34
417	P53 protein expression in lymphomas and reactive lymphoid tissue. <i>Journal of Pathology</i> , 1992, 166, 235-241.	2.1	97
418	Kaposi's sarcoma in a patient with temporal arteritis treated with corticosteroid. <i>Journal of the American Academy of Dermatology</i> , 1991, 24, 1027-1028.	0.6	10
419	Ultrastructure of 26 Cases of Ki-1 Lymphomas: Morphoimmunologic Correlation. <i>Ultrastructural Pathology</i> , 1990, 14, 381-397.	0.4	9
420	Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. <i>Clinical and Experimental Metastasis</i> , 1989, 7, 213-226.	1.7	34
421	Persistent and Generalized Lymphadenopathy: A Lesion of Follicular Dendritic Cells?: An Immunohistologic and Ultrastructural Study. <i>American Journal of Clinical Pathology</i> , 1987, 87, 716-724.	0.4	42